The Oxidative Modification of Von Willebrand Factor Is Associated with Thrombotic Angiopathies in Diabetes Mellitus
Open Access
- 31 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1), e55396
- https://doi.org/10.1371/journal.pone.0055396
Abstract
The thrombogenic activity of Von Willebrand factor (VWF) is proportional to its molecular size and inversely related to its proteolysis by ADAMTS-13. Oxidation of VWF severely impairs its proteolysis by the metalloprotease. This study was aimed at assessing in patients with type 1 and type 2 diabetes whether protein carbonyls, marker of oxidative stress, are associated with both the level and oxidation status of VWF as well as with micro- and macroangiopathic complications. Eighty-three diabetic patients (41 type 1 and 42 type 2 diabetic subjects) and their respective eighty-three healthy controls were studied after verifying the availability, through institutional databases, of clinical biochemistry records spanning at least 3 years. VWF and protein carbonyls were measured by immunoassays, whereas VWF multimers were studied by SDS-agarose gel electrophoresis. Type 2 diabetic subjects had higher levels of VWF antigen (VWF:ag), VWF activity (VWF:act) and plasma proteins’ carbonyls compared to both their controls and type 1 diabetic subjects. Moreover, high molecular weight VWF multimers and specific VWF-bound carbonyls were significantly increased in subjects with micro- and macro-angiopathic complications. In both type 1 and type 2 diabetic subjects, ADAMTS-13 activity was in the normal range. In a multivariable analysis, only VWF-bound carbonyls were significantly associated with any form of thrombotic angiopathy in the entire group of T1- and T2 diabetic patients. These data provide first evidence that not only high VWF levels but also its oxidation status and the presence of high molecular weight VWF multimers that are not observed in SDS-agarose gel electrophoresis of normal subjects are associated with thrombotic angiopathies in diabetes mellitus. These findings may help identify diabetic patients particularly at risk for these complications and elucidate a new pathophysiological mechanism of thrombotic angiopathies in this clinical setting.This publication has 51 references indexed in Scilit:
- Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam StudyJournal of Thrombosis and Haemostasis, 2012
- The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy a Randomized TrialJournal of Vascular Surgery, 2011
- Shear stress–induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 regionBlood, 2011
- Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsBlood, 2011
- Endothelial von Willebrand factor regulates angiogenesisBlood, 2011
- Oxidative Stress and Diabetic ComplicationsCirculation Research, 2010
- Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13Blood, 2010
- Oxidative risk for atherothrombotic cardiovascular diseaseFree Radical Biology & Medicine, 2009
- Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular DiseaseCirculation, 2008
- Fibrinogen β-Chain Tyrosine Nitration Is a Prothrombotic Risk Factor*Online Journal of Public Health Informatics, 2008